Terms: = Ovarian cancer AND CDKN2C, P42773, 1031, ENSG00000123080, INK4C, p18, p18-INK4C AND Treatment
12 results:
1. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Travaglino A; Raffone A; Raimondo D; Reppuccia S; Ruggiero A; Arena A; Casadio P; Zullo F; Insabato L; Seracchioli R; Mollo A
Arch Gynecol Obstet; 2022 Aug; 306(2):423-431. PubMed ID: 35034160
[TBL] [Abstract] [Full Text] [Related]
2. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract] [Full Text] [Related]
3. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
[TBL] [Abstract] [Full Text] [Related]
4. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study.
Merritt MA; Rice MS; Barnard ME; Hankinson SE; Matulonis UA; Poole EM; Tworoger SS
Lancet Oncol; 2018 Aug; 19(8):1107-1116. PubMed ID: 30029888
[TBL] [Abstract] [Full Text] [Related]
5. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.
Fruscio R; Ceppi L; Corso S; Galli F; Dell'Anna T; Dell'Orto F; Giuliani D; Garbi A; Chiari S; Mangioni C; Milani R; Floriani I; Colombo N; Bonazzi CM
Br J Cancer; 2016 Sep; 115(6):641-8. PubMed ID: 27537385
[TBL] [Abstract] [Full Text] [Related]
6. Transgenesis-mediated reproductive dysfunction and tumorigenesis: effects of immunological neutralization.
Sachdeva R; Bhardwaj N; Huhtaniemi I; Aggrawal U; Jain SK; Zaidi R; Singh O; Pal R
PLoS One; 2012; 7(11):e51125. PubMed ID: 23226476
[TBL] [Abstract] [Full Text] [Related]
7. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract] [Full Text] [Related]
8. [treatment and prognosis of low-grade malignant endometrial stromal sarcoma].
Ma SK; Zhang HT; Wu LY; Liu LY; Li B
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):74-8. PubMed ID: 17575701
[TBL] [Abstract] [Full Text] [Related]
9. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology cancer Trials Group.
Kaye SB; Paul J; Cassidy J; Lewis CR; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM; Davis JA; Reed NS; Crawford SM; MacLean A; Parkin D; Sarkar TK; Kennedy J; Symonds RP
J Clin Oncol; 1996 Jul; 14(7):2113-9. PubMed ID: 8683244
[TBL] [Abstract] [Full Text] [Related]
10. [Superficial lymph node metastasis from ovarian cancer--an analysis of 31 cases].
Hou YJ
Zhonghua Zhong Liu Za Zhi; 1990 Nov; 12(6):466-8. PubMed ID: 2076648
[TBL] [Abstract] [Full Text] [Related]
11. A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies.
Brenner DE; Garbino C; Kasdorf H; Villasanta U; Polcaro R; Yovarone J; Aisner J; Schiffer CA; Wiernik PH
Am J Clin Oncol; 1982 Jun; 5(3):291-5. PubMed ID: 6896260
[TBL] [Abstract] [Full Text] [Related]
12. Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma.
Johnsson JE; Tropé C; Mattsson W; Grundsell H; Aspegren K; Könyves I
Cancer Treat Rep; 1979 Mar; 63(3):421-4. PubMed ID: 371798
[TBL] [Abstract] [Full Text] [Related]
